Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma
- PMID: 29221258
- PMCID: PMC5708483
- DOI: 10.21037/jtd.2017.08.148
Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma
Conflict of interest statement
Conflicts of Interest: EC Smyth declares honoraria for advisory role from Five Prime Therapeutics, Bristol Meier-Squibb, Gritstone Oncology and Servier. The other author has no conflicts of interest to declare.
Comment on
-
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).Ann Oncol. 2017 Jan 1;28(1):116-120. doi: 10.1093/annonc/mdw439. Ann Oncol. 2017. PMID: 27687307 Clinical Trial.
References
-
- National Comprehensive Cancer Network. NCCN Esophageal Cancer Guidelines. 2016. Available online: https://www.nccn.org/patients/guidelines/esophageal/files/assets/common/...
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources